International Journal of Pancreatology

, Volume 7, Issue 1–3, pp 13–24 | Cite as

Composition and production of pancreatic tumor related antigens

  • Hubert E. Appert


Large numbers of specific and highly purified antibodies that react with tumor-associated antigens (TAAs) have been produced over the last decade as a result of the hybridoma technology that was developed during the previous decade. The availability of monoclonal antibodies (MAbs) rapidly led to studies of their clinical applicability. It has recently become apparent that further characterization of TAAs at the molecular level is needed before the MAbs, which react with TAAs, can have extensive use in the diagnosis and treatment of pancreatic cancer. The information that is currently available concerning the molecular composition and production of pancreatic TAAs is summarized in this presentation.

Key Words

Pancreatic cancer tumor-associated antigens 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, and Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J. Biol. Chem. 1982; 257: 14365–14369.PubMedGoogle Scholar
  2. 2.
    Magnani JL, Steplewski Z, Koprowski H, and Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19–9 in the sera of patients as a mucin. Cancer Res. 1983; 43: 5489–5492.PubMedGoogle Scholar
  3. 3.
    Herlyn M, Rodeck U, and Koprowski H. Shedding of human tumor-associated antigens in vitro and in vivo. Adv. Cancer Res. 1987; 49: 189–221.PubMedCrossRefGoogle Scholar
  4. 4.
    Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, and Pour PM. Relationship of carbohydrate antigen 19–9 and Lewis antigens in pancreatic cancel Cancer Res. 1987; 47: 5501–5503.PubMedGoogle Scholar
  5. 5.
    Ichihara T, Nagura H, Nakao A, Sakamoto J, Watanabe T, and Takagi H. Immuno- histochemical localization of CA 19–9 and CEA in pancreatic carcinoma and associated diseases. Cancer 1988; 61: 324–333.PubMedCrossRefGoogle Scholar
  6. 6.
    Kalthoff K, Kreiker C, Schmiegel W, Greten H, and Thiele H. Characterization of CA 19–9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res. 1986; 46: 3605–3607.PubMedGoogle Scholar
  7. 7.
    Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, and Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19–9 in pancreatic cancer cells in comparison with the patient’s blood group type. Cancer Res. 1988; 48: 5422–5426.PubMedGoogle Scholar
  8. 8.
    Safi F, Roscher R, Bittner R, Schenkluhn B, Dopfer H, and Beger HG. High sensitivity and specificity of CA 19–9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987; 2: 398–403.PubMedCrossRefGoogle Scholar
  9. 9.
    Itzkowitz SH, Yuan ME, Fukushi Y, Lee H, Shi Z, Zurawski V, and Hakomori S. Immunohistochemical comparison of Lea monosialosyl Lea (CA 19–9), and disialosyl Lea antigens in human colorectal and pancreatic tissues. Cancer Res. 1988; 48: 3834–3842.PubMedGoogle Scholar
  10. 10.
    Haglund C, Lindgren J, Roberts PJ, and Nordling S. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19–9. Int. J. Cancer 1986; 38: 841–846.PubMedCrossRefGoogle Scholar
  11. 11.
    Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibodies against gastrointestinal tumor-associated antigens isolates as monosialogangliosides. Int. Arch. Allergy Appl. Immunol. 1983; 71: 178–181.PubMedGoogle Scholar
  12. 12.
    Nilsson O, Mansson JE, Lindholm L, Holmgren J, and Svennerholm L. Sialosyllactotetraosylceramide: a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody. FEBS Lett. 1985; 182: 398–402.PubMedCrossRefGoogle Scholar
  13. 13.
    Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, and Pour PM. Correlative study on expression of CA 19–9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988; 48: 1435–1438.PubMedGoogle Scholar
  14. 14.
    Lan MS, Bast RC, Colnaghi MI, Knapp RC, Colcher D, Schlom J, and Metzgar R, Coexpression of human cancer-associated epitopes on mucin molecules. Int. J. Cancer 1987; 39: 68–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Lan MS, Khorrami A, Kaufman B, and Metzgar RS. Molecular characterization of a mucin-type antigen associated with human pancreatic cancer. The Du-Pan-2 antigen. J. Biol. Chem. 1987; 262: 12863–12870.PubMedGoogle Scholar
  16. 16.
    Chung YS, Ho JJL, Kim YS, Tanaka H, Nakata B, Hiura A, Motoyoshi H, Satake K, and Umeyama K. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987; 1636–1643.Google Scholar
  17. 17.
    Ho JJL, Chung Y, Fujimoto Y, Bi N, Ryan W, Yuan S, Byrd JC, and Kim YS. Mucin- like antigens in a human pancreatic cancer cell line identified by murine monoclonal antibodies span- and ypan-1. Cancer Res. 1988; 48: 3924–3931.PubMedGoogle Scholar
  18. 18.
    Leoni F, Magnani JL, Miotti S, Canevari S, Pasquali M, Sonnino S, and Colnaghi MI. The antitumor monoclonal antibody MOv2 recognizes the Lewis A hapten. Hybridoma, 1988; 7: 129–139.PubMedGoogle Scholar
  19. 19.
    Ross AH, Herlyn D, Iliopoulos D, and Koprowski H. Isolation and characterization of a carcinoma-associated antigen. Biochem. Biophys. Res. Commun. 1986; 135: 297–303.PubMedCrossRefGoogle Scholar
  20. 20.
    Linnerbach AJ, Wojcierowski J, Wu S, Pyrc JJ, Ross AH, Dietzschold B, Speicher D, and Koprowski H. Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proc. Natl. Acad. Sci. USA, 1989; 86: 27–31.CrossRefGoogle Scholar
  21. 21.
    Oikawa S, Nakazato H, and Kosaki G. Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence. Biochem. Biophys. Res. Commun. 1987; 142: 511–518.PubMedCrossRefGoogle Scholar
  22. 22.
    Ozawa S, Ueda M, Ando N, Abe O, and Shimizu N. Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum, breast and stomach. Jpn. J. Can. Res. 1988; 79: 1201–1207.Google Scholar
  23. 23.
    Neubauer A, Musch B, Thalmann U, Grosser H, Laser J, Loddenkemper R. and Huhn D. Evidence of cross-reactivity of carcinoma-specific KC4 monoclonal antibody with activated mesothelial cells and phytohemagglutinin-stimulated lymphocytes. Oncology 1988; 45: 380–383.PubMedCrossRefGoogle Scholar
  24. 24.
    Kajiji SM, Davceva B, and Quaranta V. Six monoclonal antibodies to human pancreatic cancer antigens. Cancer Res. 1987; 47: 1367–1376.PubMedGoogle Scholar
  25. 25.
    Buchler M, Dubel R, Malfertheiner P, Friss H, Schulz G, Bosslet K, and Berger HG. Immuntherapaie des fortgeschrittenen pankreaskarzinoms mit dem monoklonalen antikorper BW 494. Dtsch. med. Wschr 1988; 113: 374–380.PubMedGoogle Scholar
  26. 26.
    Reisfeld RA and Cheresh DA. Human tumor antigens. Adv. Immunol. 1987; 40: 323–377.PubMedCrossRefGoogle Scholar
  27. 27.
    Kern HF, Roher HD, von Bulow M, and Kloppel G. Fine structure of three major grades of malignancy of human pancreatic adenocarcinoma. Pancreas 1987; 2: 2–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Kern HF, Zorr A, Theiss U, Bosslet K, Schorlemmer HV, Schulz G, and Sedlacek HH. Cell biology of human pancreatic adenocarcinoma: review of tumour markers. Cancer of the Bile Ducts and Pancreas Preece PE, Cushieri A, and Rosin RD, eds., WB Saunders, Philadelphia 1989.Google Scholar
  29. 29.
    Shetye J, Frodin JE, Christensson B, Grant C, Jacobsson B, Sundelius S, Sylven M, Biberfeld P, and Mellstedt H. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A). Cancer Immunol. Immunother. 1988; 27: 154–162.PubMedCrossRefGoogle Scholar
  30. 30.
    Yoshimura R, Sakamoto K, Egami H, and Akagi M. Immunohistochemistry of human gastrointestinal cancer-associated antigen detected by monoclonal antibody PA 8–15. Jpn. J. Cancer Res. 1988; 79: 255–263.PubMedGoogle Scholar
  31. 31.
    Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, and Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19–9 levels in patients before and after treatment of carcinoma of the pancreas. J. Clin. Oncol. 1988; 6: 462–468.PubMedGoogle Scholar
  32. 32.
    Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, Ferrari AM, and DiCarlo V. Serum CA 19–9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987; 2428–2431.Google Scholar
  33. 33.
    Montz R, Klapdor R, Rothe B, and Heller M. Immunoscintigraphy and radioimmuno- therapy in patients with pancreatic carcinoma. Nucl. Med. 1986; 25: 239–244.Google Scholar
  34. 34.
    Centocor, Inc., Malvern, PA. A Phase II Study of Murine Monoclonal Antibody 17–1A in Patients with Advanced Adenocarcinoma of the Pancreas. Eastern Cooperative Oncology Group. (Est-PZ288). Suspended: April, 1989; unpublished data.Google Scholar

Copyright information

© Humana Press Inc. 1990

Authors and Affiliations

  • Hubert E. Appert
    • 1
  1. 1.Department of SurgeryMedical College of OhioToledo

Personalised recommendations